EFSA (2015) Scientific Opinion on the Safety of Caffeine, EFSA J, 13(5):4102.
Loomis D. et al. (2016) Carcinogenicity of drinking coffee, mate, and very hot beverages. Lancet Oncol, 17(7):877-878.
Bravi F. et al. (2007) Coffee drinking and hepatocellular carcinoma risk: a meta-analysis. Hepatol, 46:430-435.
Larsson S.C. et al. (2007) Coffee consumption and liver cancer: a meta-analysis. Gastroenterol, 132:1740-1745.
Bravi F. et al. (2013) Coffee reduces risk for hepatocellular carcinoma: An updated meta-analysis. Clin Gastro and Hepatol, 11:1413-1421.
Bravi F. et al. (2016) Coffee and the risk of hepatocellular carcinoma and chronic liver disease: a systematic review and meta-analysis of prospective studies. Eur J Cancer Prev, 26(5): 368-377.
Saab S. et al. (2014) Impact of coffee on liver disease a systematic review. LiverInt, 34(4):495-504.
Goh G.B. et al. (2014) Coffee, alcohol, and other beverages in relation to cirrhosis mortality: the Singapore Chinese Health Study. Hepatol, 60:661-9.
Wadhawan M. and Anandt A.C. (2016) Coffee and Liver Disease, J Clin Exp Hepatol, 6(1): 40–46.
Gressner O.A. (2009) About coffee, cappuccino and connective tissue growth factor – or how to protect your liver!? Enviro Toxicol & Pharmacol, 28(1):1-10.
Modi A.A. et al. (2010) Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatol, 51:201-209.
Walton H.B. et al. (2013) An epidemiological study of the association of coffee with chronic liver disease. Scot Med J, 58(4):217-222.
Catalano D. et al. (2010) Protective role of coffee on non-alcoholic fatty liver disease (NAFLD). Dig Dis & Sci, 55(11):3200-3206.
Birerdinc A. et al. (2012) Caffeine is protective in patients with non-alcoholic fatty liver disease. Aliment Pharmacol & Therapeu, 35(1):76-82.
Molloy J.W. et al. (2012) Association of coffee and caffeine consumption with fatty liver disease, non-alcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatol, 55(2):429-36.
Gutierrez-Grobe Y. et al. (2012) High coffee intake is associated with lower grade non-alcoholic fatty liver disease: the role of peripheral antioxidant activity. Annals Hepatol, 11(3):350-355.
Bambha K. et al. (2014) Coffee consumption in NAFLD patients with lower insulin resistance is associated with lower risk of severe fibrosis. Liver Int. 34(8):1250-8.
Wijarnpreecha K. et al. (2016) Coffee consumption and risk of non alcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Gastro Hepatol, 29(2):e8-e12.
Shen H. et al. (2016) Association between caffeine consumption and non-alcoholic fatty liver disease: a systematic review and meta-analysis. Therap Adv Gastro, 9(1):113-20.
Hodge A. et al. (2017) Coffee intake is associated with a lower liver stiffness in patients with non-alcoholic fatty liver disease, hepatitis C and hepatitis B. Nutrients, 9(1):56.
Freedman N.D. et al. (2009) Coffee intake is associated with lower rates of liver disease progression in chronic Hepatits-C. Hepatol, 50:1360.
Costentin C.E. et al. (2011) Association of caffeine intake and histological features of chronic hepatitis C. J Hepatol, Volume 54; 1123-1129.
Sasaki Y. et al. (2014) Effect of caffeine containing beverage consumption on serum alanine aminotransferase levels in patients with chronic hepatitis C virus infection: a hospital based cohort study. PLoS One, 8(12):e83382.
Gressner O.A. (2009) Less Smad2 is good for you? A scientific update on coffee’s liver benefits. Hepatol, 50, 970-978.
Gressner O.A. et al. (2009) Identification of paraxanthine as the most potent caffeine-derived inhibitor of connective tissue growth factor expression in parenchymal cells. Liver Int, 29(6):886-897.
Wang G.W. et al. (2009) Anti-hepatitis B virus activity of chlorogenic acid, quinic acid and caffeic acid in vivo and in vitro. Antiviral Res, 83(2):186-90.
Muriel P. et al. (2010) Coffee and liver disease. Fitoterapia, 81:297-305.
Ferlay J. et al. (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer, 46(4):765–81.
World Health Organisation (2015) ‘Cancer Fact Sheet no.297’. Available at: http://www.who.int/mediacentre/factsheets/fs297/en/
Sangiovanni A. et al. (2004) Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterol, 126(4):1005-14.
Burroughs A. and McNamara D. (2003) Liver disease in Europe. Alimentary Pharmacol & Therapeutics,18:54–59.
Setiawan V.W. et al. (2015) Association of Coffee Intake with Reduced Incidence of Liver Cancer and Death from Chronic Liver Disease in the US Multiethnic Cohort. Gastroenterol, 148(1):118-125.
Bamia C. et al. (2015) Coffee, tea and decaffeinated coffee in relation to hepatocellular carcinoma in a European population: multicentre, prospective cohort study. Int J Cancer, 136(8):1899-908.
Petrick J.L. et al. (2015) Coffee Consumption and Risk of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma by Sex: The Liver Cancer Pooling Project. Cancer Epidemiol Biomarkers Prev, 24(9):1398-406.
Lai G.Y. (2013) The association of coffee intake with liver cancer incidence and chronic liver disease mortality in male smokers. Br J Canc 109:1344–1351.
Leung W.W. et al. (2011) Moderate coffee consumption reduces the risk of hepatocellular carcinoma in hepatitis B chronic carriers: a case-control study. J Epidemiol & Comm Health, 65:556-558.
Jang E.S. et al. (2013) The effect of coffee consumption on the development of hepatocellular carcinoma in hepatitis B virus endemic area. Liver Int, 33(7):1092-1099.
Xiao Q. et al. (2014) Inverse association of total and decaffeinated coffee with liver enzymes in NHANES 1999-2010. Hepatol, 10.1002/hep.27367.
Alferink L.J.M. et al. (2017) Coffee and herbal tea consumption is associated with lower liver stiffness in the general population: The Rotterdam Study. J Hepatol, published online ahead of print.
Dranoff J.A. (2017) How does coffee prevent liver fibrosis? Biological plausibility for recent epidemiological observations. Hepatol, 60(2):464-467.
Salomone F. et al. (2017) Molecular Bases Underlying the Hepatoprotective Effects of Coffee, Nutrients, 9(1):85.
Tiedot on suunnattu terveydenhuollon ammattilaisille ja ravitsemusasiantuntijoille.